OTCQB:SKYE

Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday
····

Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday

Skye Bioscience shares rose 16% to $0.8293 Friday after a safety panel cleared a higher-dose cohort in its nimacimab obesity-drug study. The stock’s gain contrasted with a sector decline and comes ahead of a Nasdaq closure for Memorial Day. No neuropsychiatric adverse events were reported in the first cohort. Skye expects top-line data from the CBeyond Expansion Study in the fourth quarter.
May 24, 2026

Stock Market Today

  • ASX Mid-Cap Shares Poised for Growth as Market Shifts from Mega-Caps: VanEck Report
    May 29, 2026, 9:14 PM EDT. A VanEck report highlights that ASX mid-cap shares, historically overshadowed by large caps like BHP and Commonwealth Bank, are gaining investor interest. With bond yields at multi-decade highs and large-cap earnings under pressure, mid-caps trading at discounts to the ASX 50 now attract attention for potential earnings growth. VanEck notes that during periods of higher interest rates and slower growth, broader market leadership emerges as investors seek reliable earnings growth beyond mega-caps. Signs of this shift appear in both the U.S. and Australia, where smaller companies have delivered strong earnings surprises post-February reporting. Mid-caps' cheaper valuations amid improving earnings outlooks suggest these stocks may play a bigger role amid inflation, rising bond yields, and geopolitical risks.